For Industry
The Intellectual Property Core works to commercialize intellectual property generated by Seattle Children’s researchers, clinicians and workforce members so our discoveries and innovations can lead to better outcomes for kids. We seek to partner with industry and investment groups via out-licensing, collaborative research and creation of startups.
- A Novel CAR T cell for Treating, Inhibiting and Ameliorating HIV Infection
- A Novel Manufacturing Process for Therapeutic T cells Including CAR T cells
- A Novel Method to Prevent CAR T-cell-induced Cytokine Storm
- An Engineered Cytokine Receptor for Enhanced CAR T cells
- Bispecific CAR T cells for Solid Tumors
- caTCF1- An Engineered Transcription Factor to Supplement CAR T cell Therapy
- Dual Promoter System for Adoptive T cell Therapies
- IgM Memory B cells and Their Derivatives for Therapy and Vaccine Development
- IL1RAP CARs and CAR T cells
- iSynPro-Inducible Synthetic Promoters for Adoptive T cell Therapies
- Self-inactivating Transposase Plasmids for Genetic Engineering and Gene Therapy
- Ultrasound Mediated Non-viral Gene and Drug Delivery
- MDmetrix
- Umoja Biopharma
- Gentibio
- Wavely Diagnostics
- MicrobiomX
- Haxide
- KeyProteo
